Latest Articles

Publication Date
Dr. Amro Elfeky Joins PRM - citybiz

Dr. Amro Elfeky Joins PRM citybiz

Published: June 10, 2025, 5:07 p.m.
PRM Welcomes Dr. Amro Elfeky to Enhance Endometriosis Care in Houston and Dallas - The Manila Times

PRM Welcomes Dr. Amro Elfeky to Enhance Endometriosis Care in Houston and Dallas The Manila Times

Published: June 10, 2025, 1:47 p.m.
DWTS Pro Julianne Hough Makes Brave Decision To Share Her Fertility Journey - SKJ Bollywood News

DWTS Pro Julianne Hough Makes Brave Decision To Share Her Fertility Journey SKJ Bollywood News

Published: June 10, 2025, 10:08 a.m.
Systemic comorbidities in patients with adenomyosis.

How do comorbidities and their prevalence differ between patients with adenomyosis alone and patients with both adenomyosis and endometriosis?

Published: June 10, 2025, midnight
The Findings of Color Doppler Ultrasound in AGA Fetuses in the Third Trimester with a Drop of Two Standard Deviations of Estimated Fetal Weight in Pregnant Women.

Detection of fetal growth restriction (FGR) in appropriate for gestational age (AGA) fetuses has not been comprehensively assessed. This study aim was to evaluate the findings of Doppler ultrasound in …

Published: June 10, 2025, midnight
Endometriosis Pain Pipeline 2025: Mechanism of Action, Route - openPR.com

Endometriosis Pain Pipeline 2025: Mechanism of Action, Route openPR.com

Published: June 9, 2025, 8:39 p.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace

Published: June 9, 2025, 12:43 p.m.
EZH2 Promotes Endometriosis Progression through Estrogen Receptor and TNFα Expression - Frontiers

EZH2 Promotes Endometriosis Progression through Estrogen Receptor and TNFα Expression Frontiers

Published: June 9, 2025, 12:32 p.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:18 p.m.
How robotic surgeries are offering safer, quicker, more precise care for gynaecological cancers - The Hindu

How robotic surgeries are offering safer, quicker, more precise care for gynaecological cancers The Hindu

Published: June 9, 2025, 9:03 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!